BioMelbourne Network has announced the appointment of new board chair to succeed incumbent David Herd.
The organisation has announced that its board has elected Dr Emma Ball as its incoming chair, succeeding Mr Herd on 29 April.
Mr Herd will retire from the board, which he has served on since 2018 and chaired since 2021.
"Through his leadership, BioMelbourne Network has solidified its position within the Victorian health technologies sector, delivering positive outcomes for members and stakeholders and contributing to the advancement of life sciences," said the organisation.
Mr Herd said, "It has been an absolute privilege to serve as Chair of BioMelbourne Network. I am incredibly proud of what the Board and management have achieved during my tenure.
“BioMelbourne Network is in an excellent position to continue driving innovation and advancing the health technologies sector. I would like to express my gratitude to my fellow Board members and the entire team for their dedication to our mission and ongoing success. I would also like to sincerely thank the Victorian Government’s Department of Jobs, Skills, Industry and Regions and all of our generous partners for their continuous support and commitment to the Network.
“Dr Emma Ball is an excellent choice as new Board Chair, and I wish her every success in her role."
Dr Ball has 20 years of experience in strategic and operational roles spanning therapeutics, vaccines, diagnostics, and life sciences tools.
She is currently serving as the global head of ecosystem development at Illumina. Dr Ball joined the BioMelbourne Network Board in June 2024 and is currently serving on the finance and risk subcommittee.
"I wish to acknowledge David Herd's outstanding contribution to both BioMelbourne Network and the broader health technologies sector. David is renowned for his strategic insight, exemplary leadership, and deep expertise in government affairs and communications," said Dr Ball. “I am dedicated to building upon his legacy and advancing the crucial role BioMelbourne Network plays within our industry. I look forward to working closely with the Board, management, and our members as we continue to shape the future of life sciences."